Biotech · Private company
Foresee Pharmaceuticals Co., Ltd.
Track this companyFree. Adds Foresee Pharmaceuticals Co., Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- FP-025 100 mgPhase 3 · Severe to Critical COVID 19 With Associated ARDSClinicalTrials.gov · fetched Nov 12, 2026
- FP-025 300 mgPhase 3 · Severe to Critical COVID 19 With Associated ARDSClinicalTrials.gov · fetched Nov 12, 2026
- Leuprolide MesylatePhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- Leuprolide Mesylate, Subcutaneous injection of 42 mg LeuprolidePhase 3 · Puberty; Precocious, CentralClinicalTrials.gov · fetched Nov 12, 2026
- LMIS 50 mgPhase 3 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious PubertyPHASE3 · COMPLETED · started Jun 2, 2023ClinicalTrials.gov NCT05493709 · fetched Nov 12, 2026
- A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19PHASE2_PHASE3 · TERMINATED · started Apr 6, 2021ClinicalTrials.gov NCT04750278 · fetched Nov 12, 2026
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate CancerPHASE3 · COMPLETED · started Sep 26, 2017ClinicalTrials.gov NCT03261999 · fetched Nov 12, 2026
- Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mgPHASE3 · COMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02712320 · fetched Nov 12, 2026
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate CarcinomaPHASE3 · COMPLETED · started Aug 1, 2014ClinicalTrials.gov NCT02234115 · fetched Nov 12, 2026